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Abstract
The vast majority of Mycobacterium tuberculosis (M. tuberculosis) infected individuals are protected from developing
tuberculosis and T cells are centrally involved in this process. MicroRNAs (miRNA) regulate T-cell functions and are
biomarker candidates of disease susceptibility and treatment efficacy in M. tuberculosis infection. We determined the
expression profile of 29 selected miRNAs in CD4+ T cells from tuberculosis patients and contacts with latent M. tuberculosis
infection (LTBI). These analyses showed lower expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4+ T cells from
tuberculosis patients. Whole blood miRNA candidate analyses verified decreased expression of miR-26a, miR-29a, and miR-
142-3p in children with tuberculosis as compared to healthy children with LTBI. Despite marked variances between
individual donor samples, trends of increased miRNA candidate expression during treatment and recovery were observed.
Functional in vitro analysis identified increased miR-21 and decreased miR-26a expression after re-stimulation of T cells. In
vitro polarized Interleukin-17 positive T-cell clones showed activation-dependent miR-29a up-regulation. In order to
characterize the role of miR-29a (a described suppressor of Interferon-c in tuberculosis), we analyzed M. tuberculosis specific
Interferon-c expressing T cells in children with tuberculosis and healthy contacts but detected no correlation between miR-
29a and Interferon-c expression. Suppression of miR-29a in primary human T cells by antagomirs indicated no effect on
Interferon-c expression after in vitro activation. Finally, classification of miRNA targets revealed only a moderate overlap
between the candidates. This may reflect differential roles of miR-21, miR-26a, miR-29a, and miR-142-3p in T-cell immunity
against M. tuberculosis infection and disease.
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Introduction
Approximately one third of humankind is infected with
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of
human tuberculosis. Specific cellular immunity, especially CD4+ T
cells, is capable of containing the pathogen in the vast majority of
M. tuberculosis-infected individuals. These latently M. tuberculosis-
infected individuals (LTBI) do not develop clinical symptoms of
tuberculosis after infection, but remain at increased risk of
developing active disease especially during the first years after
M. tuberculosis infection. The exact mechanisms of how CD4+ T
cells prevent the development of active disease remain elusive.
Animal models and human genetic studies point towards
a crucial role of IFNc expressing T helper type (TH) 1 cells in
protective host immunity against tuberculosis [1]. Recent studies
showed that ‘polyfunctional’ T cells characterized by the
expression of multiple cytokine (i.e. IFNc, TNFa, IL-2) were
protective [2,3] whereas single-cytokine (i.e. either TNFa or
IWNc) expressing TH1 cells were pathognomonic [4,5]. Other T-
cell subpopulations, like Interleukin-17 producing TH17 cells, may
also influence disease susceptibility in tuberculosis, but previous
studies revealed contrary results [6–11] Thus the quantity of
a single T-cell cytokine, e.g. IFNc, is not sufficient as a marker for
protection against tuberculosis.
Little is known about the role of MicroRNAs (miRNAs) in
containing M. tuberculosis infection and preventing disease
progression. MiRNAs have been shown to fine-regulate target
genes in eukaryotic cells, including immune cells, by modulating
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protein expression at the posttranscriptional level [12]. The
maturation of miRNAs into functional regulators comprises
three main steps: I) processing of the primary-miRNA
transcripts (pri-miRNA) into the precursor miRNA (pre-miRNA)
by the nuclear RNase III enzymes Drosha and DGRC8, II)
export into the cytosol and subsequent processing into 22 bp
duplexes by the cytosolic RNase III enzyme DICER and III)
loading of the mature miRNA into the RNA-induced silencing
complex (RISC), where it binds to the 39-untranslated region
(39-UTR) of the target mRNA. MiRNAs exert their functions
mainly by degradation of the target mRNA or inhibition of
translation (reviewed in [13]). They play important roles in
many physiological processes including the development and
regulation of the immune system (reviewed in [14]). In T cells,
miRNAs have already been shown to regulate several processes
e.g. cytokine expression, polarization of distinct T-cell lineages,
homeostasis of T cells, and T-cell receptor signaling [15–20].
Indications of immune pathological effects of miRNA-mediated
regulation come from malignancies and autoimmune diseases
(reviewed in [14]), but the role of miRNAs in chronic infectious
diseases like tuberculosis is hardly defined. Recent studies
identified miRNA (miR)-29 as a central non-redundant
suppressor of IFNc [21] and increased miR-29 expression
promoted susceptibility against mycobacterial infections [22].
The aim of this study was to identify and characterize miRNAs
involved in immunity against tuberculosis. For this purpose we
initially compared expression of 29 pre-selected immune-related
miRNAs in CD4+ T cells of tuberculosis patients, healthy LTBI,
and non-M. tuberculosis infected individuals (PPDneg). A follow-up
study was then performed to determine the expression of
candidate miRNAs in whole blood of children with tuberculosis
and healthy contacts.
Results
Identification of Differentially Expressed miRNAs in CD4+
T Cells of Tuberculosis Patients and LTBI
We compared the expression of 29 miRNAs in CD4+ T cells
from peripheral blood of tuberculosis patients, LTBI, and non-
infected control donors (PPDneg). MiRNAs were selected
according to expression of T cells [23,24]. Analyses were
restricted to CD4+ T cells to avoid confounding influences of
cellular heterogeneity on RNA expression [25]. For these
analyses acute tuberculosis patients on diagnosis (i. e. prior to
onset of chemotherapy) were included. 17 of 29 miRNAs were
detectable according to defined criteria [for details see material
and methods]. Median expression levels and standard deviations
of all determined miRNAs are shown in Table 1. Four
miRNAs, namely miR-21, miR-26a, miR-29a, and miR-142-
3p, were differentially expressed between tuberculosis patients
and LTBI (P = 0.035, P = 0.005, P = 0.008, and P = 0.002,
respectively), whereas no differences were detected between
LTBI and PPDneg (Table 1 and Figure 1A). Differentially
expressed miRNAs showed decreased expression in CD4+ T
cells from tuberculosis patients as compared to LTBI and
PPDneg. Notably the level of differentially expressed miRNAs
correlated markedly in T cells from individual donors (miR-21/
miR-26a, P = 0.001; miR-21/miR-29a, P = 0.002; miR-21/miR-
142-3p P = 0.001; miR-26a/miR-29a P,0.0001; miR-26a/miR-
142-3p P,0.0001; miR-29a/miR-142-3p P,0.0001) (data not
shown). This rendered a common cause of decreased miR-21,
miR-26a, miR-29a, and miR-142-3p of CD4+ T cells from
tuberculosis patients likely.
Differential Expression of Candidate miRNAs in Blood of
Children with Tuberculosis, LTBI, and PPDneg
Limited donors numbers included for CD4+ T-cell miRNA
expression analyses prompted us to perform a follow-up case/
control study in children with tuberculosis, LTBI, and PPDneg
contacts. Here isolation of CD4+ T cells was not feasible
because of the limited sample volume. Therefore miRNA
candidate expression in whole blood was determined. Although
the expression of miRNAs was heterogeneous between individ-
uals, we detected markedly lower expression of miR-26a
(P,0.01), miR-29a (P,0.01), and miR-142-3p (P,0.05) in
children with tuberculosis as compared to children with LTBI
(Figure 2A). For miR-21 the same trend was identified without
reaching significant levels. Notably, miR-21, miR-26a, miR-29a,
and miR-142-3p expression levels were comparable between
children with tuberculosis and PPDneg children. MiR-26a and
miR-29a were lower (both P,0.05) in PPDneg as compared to
children with LTBI (Figure 2A). Time course analyses of CD4+
T cells from selected tuberculosis patients revealed markedly
increased miRNA candidate expression during the first months
of chemotherapy (data not shown). Therefore we determined
miRNA expression in children with tuberculosis also during
treatment (3 months after onset of therapy) and after recovery
(12 months after onset of therapy) (Figure 2B). We identified
trends of increased miRNA candidates expression (P = 0.07 for
miR-21; P = 0.12 for miR-26a) after recovery as compared to
active disease (Figure 2B). We concluded that miRNA candidate
expression in peripheral blood of children largely reflected
differences between CD4+ T cells. Next we analyzed a possible
role of miRNA candidates during T-cell activation and
differentiation.
Expression of miR-21, miR-26a, miR-29a and miR-142-3p
after in vitro Re-stimulation of Naı¨ve T Cells
In an initial attempt to determine the role of candidate
miRNAs in T-cell activation and differentiation, we determined
expression of miR-21, 26a, 29a, 142-3p after in vitro restimula-
tion. Naı¨ve CD4+ T cells were stimulated with crosslinking
aCD3/CD28 antibodies in vitro and expression of the miRNA
candidates was determined. As a control we used miR-155 that
is described to be up-regulated upon T-cell receptor-specific
Figure 1. Four miRNAs are differentially expressed in CD4+ T
cells from tuberculosis patients and LTBI. Expression of miR-21
(triangles), miR-26a (squares), miR-29a (circles), and miR-142-3p
(diamonds) in CD4+ T cells from tuberculosis patients (TB) (black
symbols, n = 6), LTBI (grey symbols, n = 7), and PPD negative healthy
controls (PPDneg) (open symbols, n = 3). Median expression of
candidate miRNAs relative to the housekeeping gene RNU48 is shown.
Significant differences are indicated as asterisks (* for p,0.05; ** for
p,0.01, Mann-Whitney U-test).
doi:10.1371/journal.pone.0061609.g001
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stimulation [26]. Following aCD3/CD28 stimulation expression
of this control miRNA was increased up to 100-fold already on
day three (P = 0.02) (Figure 3A). MiR-21 showed a tendency of
increased expression on stimulation (up to 10-fold seven days
post stimulation) (P = 0.1) (Figure 3A). MiR-26a expression
decreased until day three post stimulation and remained
relatively stable until day seven (P = 0.02) (Figure 3). MiR-29a
and miR-142-3p showed only moderate expression differences
with miR-142-3p being slightly decreased (Figure 3). Notably,
similar changes in miR-21 expression were detected after
PBMC stimulation from LTBI with M. tuberculosis-specific
antigen PPD (Figure 3B). A trend of decreased expression was
also detected for miR-26a on day seven (Figure 3B). We
concluded that miR-21 expression increased upon activation of
naı¨ve CD4+ T cells in vitro whereas miR-26a decreased upon T-
cell activation in vitro.
Expression of miR-21, miR-26a, miR-29a and miR-142-3p
in Human TH1 and TH17 Clones
IFNc-secreting TH1 cells are crucial for protective immunity
against M. tuberculosis infection [27–29]. Polarization of T cells
towards functional distinct TH-subsets (e.g. TH17) may affect
susceptibility and protection against tuberculosis. Consequently
we analyzed expression of candidate miRNAs in polarized T
cell clones. T cell cloning (for details see Methods) resulted in
IFNc-expressing TH1 and IL-17-expressing TH17 clones.
Comparison of miRNA-expression between resting TH1 and
TH17 clones revealed no differences for candidate miRNAs
(Figure 4A), whereas miR-155 expression was increased in TH1
clones (P = 0.03) (Figure 4A). Notably, activation of T-cell clones
with PMA/Ionomycin increased miR-29a expression of TH17
clones (P = 0.01) but not of TH1 clones (Figure 4B). No
differences were detected for miR-21, miR-26a, miR-142-3p
and miR-155 upon activation (Figure 4B).
Similar IFNc Expression in CD4+ T Cells from Children
with Tuberculosis and LTBI and No Correlation between
IFNc and miRNA Candidate Expression Level
IFNc has recently been identified as a target of miR-29a
[21,22]. Since miR-29a was differentially expressed between
children with tuberculosis and LTBI, we compared proportions
of IFNc expressing T cells between these study groups and in
children with tuberculosis during treatment and recovery. IFNc
expression was comparable between children with tuberculosis
and LTBI after in vitro re-stimulation with M. tuberculosis-specific
PPD (Figure 5A, upper graphs) and also for stimulation with
staphylococcal superantigen SEB (data not shown). No differ-
ences were detected when comparing IFNc expression between
different time points of children with tuberculosis under
chemotherapy and recovery (Figure 5A, upper left graph).
Since IFNc and miRNA expression varied between individuals
we also compared expression of IFNc and miR-29a in
individual children with tuberculosis under chemotherapy and
after recovery. No dependency between miR-29a and IFNc
expression was detected (R2 = 0.03; P = 0.36) (Figure 5A, lower
graph).
Figure 2. MiRNA candidate expression of peripheral blood cells from children with tuberculosis and LTBI. Expression of miR-21
(triangles), miR-26a (squares), miR-29a (circles), and miR-142-3p (diamonds) in whole blood is shown for children with tuberculosis (TB, black
symbols), healthy latently M. tuberculosis children (LTBI, grey symbols), and PPD negative contacts (PPDneg, open symbols) (A) as well as for children
with tuberculosis under therapy and recovery (B). Each symbol indicates miRNA candidate expression for an individual donor relative to
‘housekeeping’ control RNU48. Significant differences are indicated as asterisks (* for P,0.05; ** for P,0.01, Mann-Whitney U-test). Exact P-values
(Mann-Whitney U-test) are indicated for tendencies.
doi:10.1371/journal.pone.0061609.g002
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Modulation of miR-29a Expression in Primary Human
CD4+ T Cells
Results of ex vivo miR-29a and in vitro IFNc analyses may be
confounded by several factors. Therefore, to validate these
experiments, we modulated miR-29a expression in primary
human T cells. Endogenous miR-29a expression was suppressed
using specific antagomir assays (for details see methods). Antag-
omirs against human miR-16 and C. elegans miR-67 have been
used as controls in these experiments. Both antagomirs against
human miR-16 and miR-29a down-regulated respective targets
(miR16, mean 70%; miR-29a, mean 58%) in CD4+ T cells,
whereas negative control C. elegans miR-67 had no effects
(Figure 5B, upper graphs). Activation of T cells using PMA/
Ionomycin in vitro stimulation induced about 50% IFNc producing
T cells (Figure 5B, lower left graph). Notably decreased miR-29a
expression did not affect the proportions of IFNc producing T cells
(Figure 5B, lower left graph). Also the cellular protein expression
level of IFNc (determined by single cell median fluorescence
analysis) was not influenced by miR-29a suppression (Figure 5B,
lower right graph). The same hold true for TNFa producing T
cells in this assay (data not shown). We concluded that suppression
of miR-29a did not affect IFNc expression in our assay and
therefore other target genes maybe regulated by differential
miRNA expression. Especially common targets of the examined
miRNAs maybe of interest in this context.
Common Immunological Targets of miRNAs and PTEN
Protein Evaluation Compared to miR-21, 26a, and 29a
Expression
Predicted miR-21, miR-26a, miR29a, and miR-142-3p targets
from the miRGen Internet platform were determined for
expression in immunological tissues using Unigene Internet
database (for details see Materials and Methods). The predicted
candidate miRNA targets expressed in immunological tissues (i.e.
201 genes for miR-21; 287 genes for miR-142-3p; 515 genes for
miR-26a; and 580 genes for miR-29a) were then analyzed for
overlapping target groups. Figure 6A shows a venn diagram of
overlapping miRNA targets. The overall overlap of target genes
between the candidate miRNAs was small and not a single gene
was predicted target of all four miRNAs. One common target
predicted for miR-21, miR-26a, and miR-29a was PTEN,
a regulatory protein involved in T cell receptor signaling [30].
Therefore ex vivo PTEN protein expression in lymphocytes of
children with tuberculosis and contacts was compared. We found
no evidence for a correlation of miR-21 (Figure 6B; upper left
graph), miR-26a (Figure 6B; upper right graph), or miR-29a
(Figure 6B; lower graph) with PTEN protein levels. Ongoing
studies aim at validating additional common targets of miRNA
candidates to claryfy the role of miR-21, miR-26a, miR-29a, and
miR-142-3p expression in tuberculosis.
Figure 3. Candidate miRNA expression after activation of naı¨ve T cells and PPD-specific PBMC stimulation. MiRNA expression was
analyzed three and seven days after in vitro activation of naı¨ve T cells from healthy donors (n = 4) with aCD3/CD28 and for PBMCs of LTBI (n = 3)
stimulated with M. tuberculosis purified protein derivative (PPD). Expression of the miRNAs was normalized to the housekeeping gene RNU48 and is
shown relative to the respective non-stimulated control (dotted line). Median expression and range is shown. Significant differences are indicated as
asterisks (* for P,0.05, Kruskal-Wallis test).
doi:10.1371/journal.pone.0061609.g003
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Discussion
MiRNAs are involved in the regulation of T-cell immunity and
failure may lead to malignancies or autoimmune diseases. The
present study provided evidence for a role of miR-21, miR-26a,
miR-29a, and miR-142-3p in the immune response against human
tuberculosis, a chronic infectious disease. The candidate miRNAs
identified in this study were expressed at lower levels in T cells of
tuberculosis patients and increased during chemotherapy in
individual donors. Analyses of miRNA candidates in whole blood
of children with tuberculosis and contacts verified lower miR-26,
miR-29a, and miR-142-3p expression in children with tubercu-
losis. MiR-21 and miR-26a were shown to be regulated during T-
cell activation. Initial experiments to modulate miR-29a expres-
sion in primary T cells did not suggest a suppressive role of miR-
29a on IFNc regulation.
Host immunity against M. tuberculosis is complex and different
innate and adaptive immune components are crucial for pro-
tection against disease [1]. Because of the unambiguous crucial
role of CD4+ T cells, we initially focused on this population for
identification of candidate miRNAs in the present study. The
expression of miR-21, miR-26a, miR-29a, and miR-142-3p was
homogeneous within the study groups and already moderate
numbers of tuberculosis patients, LTBI, and PPDneg were
sufficient to detect significant differences. In addition, the level
of differentially expressed miRNAs of tuberculosis patients and
controls correlated significantly and therefore, common regulation
for miR21, miR-26a, miR-29a, and miR-142 was likely. Previous
studies identified key genes for microRNA regulation and a central
factor was c-myc [31]. The oncogene c-myc is a transcription
factor that regulates several genes and recently it became clear that
c-myc also dramatically reprograms miRNA expression [31].
Besides regulating the important miR-17-92 cluster, c-myc has
also been shown to suppress miR-26a and miR-29 family members
[32,33]. The related transcription factor n-myc has been identified
as a suppressor of miR-21 [34]. Previously we showed that c-myc
is up-regulated in T cells from tuberculosis patients prior to
therapy [35]. It is tempting to speculate that c-myc is part of the
mechanisms leading to concordant down-regulation of miR-26a,
miR-29a (and probably miR-21). It remains elusive whether miR-
142-3p is also regulated by c-myc. Notably the promotor of c-myc
has been identified as a target of nucleoside diphosphate kinase
secreted by M. tuberculosis [36]. Future studies will address the
question if pathognomonic differences in host miRNA expression
were caused by direct interaction of M. tuberculosis virulence factors
with host genes.
MiR-21 and miR-26 showed differential expression after in vitro
re-stimulation. Here miR-21 was up-regulated and miR-26a was
Figure 4. Expression of candidate miRNAs in TH1 and TH17 clones. Expression of miR-21 (triangles), miR-26a (squares), miR-29a (circles), miR-
142-3p (diamonds), and miR-155 (hexagons) was compared between IFNc-expressing TH1 (open symbols, n = 11) and IL-17-expressing TH17 clones
(black symbols, n = 9) of healthy donors prior to (A) and after in vitro activation (B). Expression of candidate miRNAs was normalized to the
housekeeping gene RNU48. Median expression and range is shown. Significant differences are indicated as asterisks (* for P,0.05, Mann-Whitney-U
test). (B) MiRNA expression after 12 h in vitro re-stimulation with PMA/Ionomycin. Relative expression to the respective non-activated control is
shown (dotted line).
doi:10.1371/journal.pone.0061609.g004
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down-regulated after TCR-specific in vitro stimulation of naı¨ve T
cells and M. tuberculosis specific T cells of LTBI. Recently
a comprehensive study of miRNA expression in T cells detected
decreased expression of miR-26a upon in vitro T-cell activation
[37]. Our results confirm miR-26a down-regulation after T-cell
receptor specific stimulation and likely reflect involvement in T-
cell activation and development.
To examine possible roles of the identified candidate miRNAs
we performed target gene analysis and focused on targets
expressed in immunological tissues (i.e. blood, lymph node, lymph,
spleen, thymus). The overlap between target genes was moderate
and none of these were predicted for all four miRNAs. Only eight
targets were predicted for three candidate miRNAs and classifi-
cation did not reveal pathways dominantly targeted by miRNA
candidates (data not shown). Hence we considered it likely that
distinct immunologic processes are involved by differential
miRNA expression. A crucial T-cell regulator identified as target
of miR-21, miR-26a, and miR-29a is PTEN (phosphatase and
tensin homolog deleted on chromosome 10). PTEN is a lipid
phosphatase that negatively regulates antigen-activation of T cells
by inhibiting the phosphoinositide 3-kinase (PI3K) signaling
pathway [38]. Recently Huang et al. found that cell lines deficient
for PTEN have an increased susceptibility to Mycobacterium bovis
BCG infection [39]. Initial experiments have been performed to
characterize PTEN protein expression in lymphocytes of children
with tuberculosis and LTBI. The fact that we did not detect
a correlation between miR-21, 26a, or 29a expression and PTEN
protein levels did not exclude a possible role of PTEN regulation
since other factors may confound analyses. In vitro modulation of
miRNA candidate expression is currently performed to verify
candidate miRNA targets.
A key factor for susceptibility against tuberculosis is IFNc and
the underlying TH1 immune response. It is a matter of discussion if
protective TH1 immunity against tuberculosis may be impeded by
other T helper subtypes (i.e. TH2, TH17) in a process called
immune polarization. Analysis of miRNA candidate expression
from ex vivo isolated TH17 cells was not feasible because of the low
frequency of this subpopulation in peripheral blood [40].
Therefore we compared polarized TH1 and TH17 clones (TH2
clones could not be generated) for candidate miRNA expression.
Differences were detected for miR-29a that was up-regulated after
in vitro activation in TH17 but not in TH1 clones. This is in
accordance with previous findings showing an IFNc suppressive
function of miR-29 [22]. In a recent study miR-29a reconstitution
alone corrected aberrant IFNc expression induced in the absence
of miRNAs [21]. Furthermore, Ma et al. showed IFNc itself is
a target for miR-29a and that infection of mice with intracellular
bacteria led to down-regulation of miR-29a expression in T cells.
In an attempt to characterize the effect of miR-29a expression
we compared IFNc expression in children with tuberculosis and
LTBI as well as expression of both (miR-29a and predicted target
IFNc) in lymphocytes of individual donors but detected no
dependency between these factors. In addition we determined the
influence of miR-29a suppression on IFNc production of primary
human T cells using antagomir technology but did not detect
differences of IFNc expression upon inhibition of miR-29a
expression (about 58% reduction). Several reasons may account
for these seemingly contrary results. First, approximately 3-fold
reduction may not be sufficient for induction of additional IFNc
producing T cells, taking into account that PMA/Ionomycin
stimulation activated high proportions of IFNc expression T cells
(about 50% of all T cells). Second, given the dominant TH1
response – marked by IFNc production – induced by in vitro
stimulation, it is possible that ex vivo miR-29a expression levels in T
cells were too low to inhibit IFNc expression. In this case down-
regulation would be without consequences but over-expression of
miR-29a may lead to IFNc-inhibition. Ongoing experiments in
our laboratory address these questions. Finally, it is tempting to
speculate that there are differences in the regulation of IFNc by
miR-29 between animal models and humans. E.g. there may be
additional miRNAs that suppress IFNc in humans and, hence,
down-regulation of miR-29a was not sufficient.
We consider the present study an initial step to characterize the
role of microRNAs in tuberculosis. Consistent pattern of
differentially expressed miR-21, miR-26a, miR-29a, and miR-
142-3p suggested a role of these candidates in T-cell immunity
during tuberculosis disease and recovery. Further studies will have
to be performed to elucidate the processes targeted by candidate
miRNAs and to reveal if miRNAs are possible targets for disease
intervention strategies in tuberculosis.
Table 1. Median Expression of miRNAs in PPDneg donors, LTBI
and tuberculosis patients.
PPDneg LTBI Tuberculosis
Median SD Median SD Median SD
let-7a 0,0008 0,0006 nd nd nd Nd
miR-15a 0,0005 0,0003 0,0003 0,0013 0,0003 0,0008
miR-17-3p 0,1401 0,0311 0,1259 0,0403 0,071 0,02
miR-21 0,0393 0,0161 0,0438 0,0252 0,0121 0,0047
miR-23a 0,00005 0,00005 nd nd nd Nd
miR-25 0,0032 0,0005 0,0027 0,0083 0,0015 0,0027
miR-26a 0,0808 0,0409 0,0928 0,0411 0,0148 0,0113
miR-27a 0,0016 0,001 0,0025 0,0054 nd Nd
miR-29a 0,0687 0,0122 0,0815 0,0467 0,0233 0,0137
miR-30a* 0,728 0,0443 0,07 0,0294 0,036 0,0982
miR-98 nd nd nd nd nd Nd
miR-99b 0,0003 0,0001 nd nd nd Nd
miR-101 0,0008 0,0004 0,0014 0,001 nd Nd
miR-106a 0,1478 0,0215 0,1185 0,0455 0,08 0,0222
miR-106b 0,0047 0,0011 0,003 0,0016 0,0018 0,0028
miR-122 nd nd nd nd nd Nd
miR-126 0,0022 0,0007 0,0011 0,0013 0,0023 0,0055
miR-142-3p 0,8261 0,3628 0,6404 0,417 0,1 0,0909
miR-143 nd nd nd nd nd Nd
miR-144* nd nd nd nd nd Nd
miR-146a 0,3294 0,0417 0,3099 0,1966 0,2069 0,1075
miR-150 2,459 0,7761 3,8087 1,6389 2,0281 1,3939
miR-155* nd nd nd nd nd Nd
miR-181a-1 0,001 0,0003 0,0007 0,0009 nd Nd
miR-191 0,1224 0,366 0,0691 0,022 0,0558 0,0526
miR-203 nd nd nd nd nd Nd
miR-218 nd nd nd nd nd Nd
miR-223 0,8505 0,7369 0,1425 0,3888 0,1249 0,8014
miR-455-5p nd nd nd nd nd Nd
RNU481 na na na Na
1control; nd: miRNA not detectable in at least two donors.
doi:10.1371/journal.pone.0061609.t001
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Materials and Methods
Study Design and Samples
A pilot study was conducted in order to compare miRNA
expression among tuberculosis patients and healthy contacts
recruited at the University hospital Hamburg-Eppendorf and at
the Asklepios Center for Respiratory Medicine and Thoracic
Surgery Munich-Gauting, Germany Altogether 16 donors were
recruited and peripheral blood (20 ml) was obtained from each
donor. Participants were categorized according to the following
criteria:
Healthy contacts of tuberculosis patients with a positive T-cell
response against purified protein derivative (PPD) of M. tuberculosis
(Statens Serum Institute) (as described previously [41]) were
termed latently M. tuberculosis infected (LTBI) (n = 6; median age
32 y; range 29–58 y).
Healthy donors without PPD-specific immunity were termed
PPD negative (PPDneg; n = 3).
Diagnosis of active tuberculosis was based on patient history,
chest X-ray, tuberculin skin test, QuantiFERON-TB-GoldH test,
and mycobacterial culture (TB patients; n = 7; median age 35 y;
range 22–52 y).
T-cell clones (TCCs) have been generated using buffy coat cells
from anonymous donors. All donors gave written informed
consent. The local ethics committee approved this study
(Aerztekammer Hamburg, WF-07/09).
In the follow-up prospective cohort study, we recruited 22
children with tuberculosis (median age, 5 y; range 0–16 y), 14
children with LTBI (median age 8 y; range 3–16 y), and 19 non-
M. tuberculosis infected (PPDneg) children (median age, 3 y; range,
0–11 y) at the Department of Pediatric Pneumology and
Immunology, Charite´ in Berlin, Germany. All children received
follow-up examinations three and twelve months after diagnosis.
Peripheral blood (max. of 7 ml) was taken at all time points to
perform IGRA tests and isolation of peripheral blood mono-
nuclear cells (PBMCs). Of 22 children with tuberculosis initially
recruited, 18 were included three months, and of these 13 were
Figure 5. IFNc and miR-29a expression of infected children and ectopic miR-29a suppression in T cells. (A) IFNc expression after short-
term in vitro re-stimulation of PBMC from children with tuberculosis (upper left graph) prior to chemotherapy (black symbols), three months under
chemotherapy (grey symbols), after recovery (open symbols), as well as children with LTBI (upper right graph) with M. tuberculosis-specific PPD is
shown. Proportions of IFNc expressing CD4+ T cells (y-axis) for different time points after treatment onset of patients (x-axis) are depicted. Each
symbol represents data from an individual patient with tuberculosis (hexagon) or LTBI (filled trigon). Ex vivo whole blood miR-29a expression (x-axis)
in comparison to the proportions of IFNc expressing CD4+ T cells (x-axis) for individual children with TB under therapy (circles) is shown in the lower
graph. (B) Modulation of miR-29a expression (upper left graph) and control miR-16 (upper right graph) of CD4+ T cells by specific antagomirs (Homo
sapiens (Hsa)-29a, Hsa-16, and Caenorhabditis elegans (Cel)-67) and effects on IFNc expression (lower graphs) are depicted. IFNc expression of
activated CD4+ T cells after miR-29a or miR-16 suppression is shown as proportions of IFNc+ cells (lower left graph) or as the IFNc expression level per
cell (indicated by median fluorescence intensities (MFI)) (lower right graph).
doi:10.1371/journal.pone.0061609.g005
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included 12 months after onset of therapy. Children were classified
according to the following criteria:
Children with LTBI had reported contact to a contagious
tuberculosis index case, had positive tuberculin skin test (TST),
and Interferon gamma (IFNc-release assay (IGRA, QuantiFER-
ONH-TB Gold) but showed no clinical symptoms of tuberculosis
(including chest X-ray imaging without pathological findings).
Children with tuberculosis were diagnosed based primarily on
patient history (especially reported contact to index case) and chest
X-ray and diagnosis was supported by positive TST or IGRA in
all included cases. Children with LTBI and children with
tuberculosis were treated according to German guidelines. All
legal guardians of included children gave written informed
consent. This study was approved by the local ethics committee
(EA4/019/09).
MiRNA Isolation, Reverse Transcription, and Analysis
MiRNAs were isolated from T cells (minimum of 56106) or
frozen blood pellets (of 500 ml heparanized blood) using the
mirVanaTM miRNA Isolation Kit (Ambion) following manufac-
turer’s instructions. Reverse transcription was performed with
the TaqManH MicroRNA Reverse Transcription Kit (Applied
Biosystems) using two different methods: I) for plate assay
analyses using the MegaplexTM RT Primers Human Pool A and
B (500 ng RNA each) (Applied Biosystems), II) for single
TaqManH miRNA Assays containing RNA-specific RT primer
(100 ng RNA) (Applied Biosystems) following manufacturer’s
instructions. For quantitative PCR-based detection of miRNA
either a custom-designed 96-well plate (Applied Biosystems) for
detection of 29 candidate miRNAs (Table 1) or single
TaqManH miRNA assays (Applied Biosystems) were used. For
the 96-well plates reverse transcription method I and for the
single assays reverse transcription method II was used. The
‘housekeeping’ control gene RNU48 (official symbol:
SNORD48) was applied. The real time PCR was performed
in triplicates. Median expression of candidate miRNAs (Ct)
relative to the housekeeping gene was calculated (DCt).
MiRNAs that were detectable in less than 5 tuberculosis
patients and 6 LTBI were excluded from further analysis and
termed not detectable (nd). For in vitro stimulated T cells, DCt
values of the respective non-stimulated sample were subtracted.
Enrichment of Total and Naive CD4+ T Cells
Peripheral blood mononuclear cells (PBMC) were isolated from
20 ml heparinized blood by density centrifugation (Biocoll, Gibco)
and enrichment of CD4+ T cells was performed using the
magnetic cell sorting system (IMag, Becton Dickinson) following
manufacturer’s instructions. The purity of enriched T-cell
populations was generally higher than 95% as determined by
flow cytometry. Naı¨ve CD4+ T cells for in vitro stimulation
experiments were enriched using ‘untouched’ magnetic cell
separation (MACS, Miltenyi) following manufacturer’s instructions
and as described before [42].
CD4+ T-cell subpopulation enrichment for ex vivo miRNA
analyses was performed by fluorescence-activated cell sorting
(FACS) using the following antibodies: CD4 (APC-H7, clone
RPA-T4, BD), CD45RA (FITC, clone HI100, BD), CD3 (PerCP,
clone SK7, BD) and CCR7 (PE-Cy7, clone 3D12, BD). Cell
sorting was performed using a FACS-ARIA III (BD). A minimum
of 2.56105 sorted cells was acquired and immediately frozen at
220uC for miRNA isolation.
Figure 6. Target genes and overlaps for miR-21, miR-26a, miR-29a and miR-142-3p. (A) A Venn diagram indicates the overlap of target
genes for miR-21, miR-26a, miR-29a and miR-142-3p. Common targets of at least three candidate miRNAs are listed by name. (B) Comparison
between expression miR-21 (upper left graph), miR-26a (upper right graph), miR-29a (lower graph) and protein expression of the common target
PTEN in lymphocytes from children with tuberculosis (n = 19) and LTBI (n = 3) is shown. We indicate relative miRNA expression to house keeping gene
RNU48 by quantitative PCR and compare this to PTEN protein expression determined by flow cytometry using median fluorescence intensity (MFI)
analysis. Each symbol represents data from an individual donor.
doi:10.1371/journal.pone.0061609.g006
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In vitro Stimulation of T Cells
Naı¨ve T cells (1.26106) were stimulated with crosslinking
aCD3/CD28 Dynabeads (Dynal) (2,5 ml/ml) in 96-well microtiter
plates containing 200 ml X-Vivo15 medium (supplemented with
1% Penicillin/Streptomycin). PBMCs of LTBI were stimulated
with PPD of M. tuberculosis. Samples were incubated for three or
seven days at 37uC and 5% CO2. Afterwards cells were
immediately frozen at 220uC for miRNA analyses. Short term
(overnight) re-stimulation of T cells with M. tuberculosis specific
PPD for analysis of IFNc expressing T cells proportions was
performed as described previously [41].
Intracellular PTEN Protein Expression
PBMCs were fixed in para-Formaldehyde (2%) for 10 min at
37uC and were then permeabilized using Phosflow buffer 3 (BD)
following manufacturer’s instructions. After single staining with
PTEN-specific PE-labeled antibodies (BD) (to avoid confounding
effects of multi-color analyses), cells were wash twice and
fluorescence intensities were determined using a FACS-Canto
flow cytometer (BD). Median fluorescence intensities (MFI) have
been shown.
Generation of TH1 and TH17 Clones
TH1 and TH17 clones were generated as described previously
[40]. In brief, purified PBMCs (26107) were stained with
monoclonal antibodies (anti-CD4 APC-Cy7, BD and anti-
CD161 FITC, Miltenyi Biotec), and CD4+ CD161+ T cells were
sorted into 96-well round bottom plates (1, 2, 3, 5 or 10 cells/well)
using a FACS Aria II (BD). Prior to sorting irradiated heterologous
antigen presenting cells (16105 cells/well) and aCD3/CD28
Dynabeads (0,1 mL/well) were added. On day 0, 7, 14, and 21 IL-
2 (20 U/ml) was added. After 14 days expanded T-cells clones
were counted for each plate. Only T-cells clones from plates with
less than 37% positive wells were selected to ensure derivation
from a single precursor cell. The cytokine profile of the TCC was
determined after PMA/Ionomycin activation over night as
described previously [40]. TCC with distinct IFNc and IL-17
expression were analyzed miRNA candidate levels.
Modulation of MiRNA Expression Using Antagomirs
Transfection of PBMCs with antagomir-29a and control
antagomirs for miR-16, and C. elegans cel-miR-67 (all Dharmacon)
was performed following manufacturer’s instructions. Briefly,
PBMCs (1.56105 cells/well ) were seeded in 96-well round
bottom plates containing X-Vivo15 w/o antibiotics (200 mL/well)
and aCD3/CD28 Dynabeads (2 mL/well). After 16 h at 37uC and
5% CO2 transfection was done. Antagomirs (5 mM in siRNA
buffer (Dharmacon)) were diluted 1:10 with X-Vivo15 and
transfection-solution was prepared mixing DharmaFECT4 (Dhar-
macon) with X-Vivo15 in a 0.5/10 Ratio. After incubation for
5 min at room temperature (RT) the antagomir-solution was
added to the transfection-solution in the ratio of 1:1 and was
incubated for 20 min at RT. X-Vivo15 was added in a ratio of 1:5.
Stimulated cells were centrifuged and the supernatant was
discarded. The prepared solution of antagomir, DharmaFECT4,
and X-Vivo15 was added (100 mL/well) and the cells were
incubated for 48 h at 37uC and 5% CO2. Subsequently cytokines
(i.e IFNc, TNFa, IL-2) and miRNA expression was analyzed by
flow cytometry and real-time PCR, respectively.
Identification and Functional Annotation of miRNA
Targets
We predicted miRNA targets on the miRGen internet platform
(www.diana.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets.cgi) us-
ing PicTar, TargetScanS, miRanda (miRBase), DIANA-microT.
Only targets predicted by a minimum of two software algorithms
were selected for further analyses. The Unigene EST profile
viewer was applied to constrain predicted miRNA candidate
targets to those expressed in at least two of five immune tissues (i.e.
blood, lymph node, lymph, spleen, thymus). Target annotations
and clustering were done using the DAVID internet platform
(http://david.abcc.ncifcrf.gov/) Medium classification stringency
was chosen and p-values adjusted for multiple comparisons
(according to Benjamini-Hochberg) are shown.
Statistical Analyses
Non-parametric tests have been applied throughout since
moderate sample numbers were not sufficient to verify normal
distributions. For comparison of miRNA expression between study
groups and T-cell clones we applied the Mann-Whitney U-test.
The Kruskal-Wallis test has been applied for comparison of
miRNA expression in naı¨ve T cells at different time points after
in vitro stimulation. For correlation analyses of miRNA candidates
the Spearman test was used.
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